Geldanamycin- Biotin__Hsp90 inhibitor WAY-362450
Product Name
Geldanamycin- Biotin
Description
Hsp90 inhibitor
Purity
>98%
CAS No.
30562-34-6
Molecular Formula
C55H87N7O17S
Molecular Weight
560.6
Storage Temperature
-20ºC
Shipping Temperature
Shipped Ambient
Product Type
Inhibitor
Solubility
Soluble in DMSO
Source
Synthetic
Appearance
Purple Solid
SMILES
Cemail protected1CC@@H(C@@H(email protected(/C=C(/C@@H(email protected(/C=CC=C(C(=O)NC2=CC(=O)C(=C(C1)C2=O)OC)/C)OC)OC(=O)N)C)C)O)OC
InChI
InChI=1S/C29H40N2O9/c1-15-11-19-25(34)20(14-21(32)27(19)39-7)31-28(35)16(2)9-8-10-22(37-5)26(40-29(30)36)18(4)13-17(3)24(33)23(12-15)38-6/h8-10,13-15,17,22-24,26,33H,11-12H2,1-7H3,(H2,30,36)(H,31,35)
InChIKey
QTQAWLPCGQOSGP-KSRBKZBZSA-N
Safety Phrases
Classification: Harmful. May be harmful if inhaled, swallowed or absorbed through skin.
Safety Phrases:
S22 – Do not breathe dust
S24/25 – Avoid contact with skin and eyes
S36/37/39 – Wear suitable protective clothing, gloves and eye/face protection
Risk Phrases:
R68- Possible risk of irreversible effects
Cite This Product
Geldanamycin- Biotin (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-112)
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19125518
Alternative Names
(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo16.3.1
docosa-1(21),4,6,10,18-pentaen-9-yl carbamate
Research Areas
Cancer, Heat Shock
PubChem ID
5288382
Scientific Background
Geldanamycin is a benzoquinoid ansamycin produced by Streptomyces hygroscopicus. It binds specifically to heat shock protein HSP90 and downregulates target proteins including tyrosine kinases, steroid receptors, transcription factors and cell cycle regulatory kinases (1,2). It induces the inactivation, destabilization and eventual degradation of HIF-1α (3). It is also an inhibitor of pp60src tyrosine kinase and of c-myc gene expression in murine lymphoblastoma cells. It inhibits the transforming activity of abl, erbB, fps, src, and yes (4). Geldanamycin is capable of destabilizing several oncogene and proto-oncogene products; it is a potent inhibitor of the nuclear hormone receptor family (5). It protects against α-synuclein toxicity to dopaminergic neurons in Drosophila, and destabilizes mutant p53 protein from a number of breast, leukemic, and prostate cell lines (6). Inhibits basal and hypoxia-induced expression of c-Jun (IC50=75nM) and abolishes hypoxia-induced increase in c-Jun N-terminal kinase (JNK) activity. Inhibits telomerase activity through inhibition of HSP90, a chaperone required for the assembly and activation of telomerase in human cells (6). It is ~10-fold more potent than herbimycin A. Looking for more information on HSP90? Visit our new HSP90 Scientific Resource Guide at http://www.HSP90.ca.
References
1. Whitesell L., et al. (1994) Proc. Natl. Acad. Sci. USA 91:8324.
2. Neckers L. (2002) Trends Mol. Med. 8: S55.
3. Mabjeesh N.J., et al. (2002) Cancer Res. 62: 2478.
4. Chavany C., et al. 1996) Amer. Society Biochem Mol Bio. 9: 4974-4977.
5. Villa R., et al. (2003) Carcinogenesis. 24(5): 851-9.
6. Yamaki H., Iguchi-Ariga S.M., and Ariga H. (1989) J Antibiot (Tokyo). 42(4): 604-10.
Hsp90 inhibitor
Safety Phrases:
S22 – Do not breathe dust
S24/25 – Avoid contact with skin and eyes
S36/37/39 – Wear suitable protective clothing, gloves and eye/face protection
Risk Phrases:
R68- Possible risk of irreversible effects
docosa-1(21),4,6,10,18-pentaen-9-yl carbamate
2. Neckers L. (2002) Trends Mol. Med. 8: S55.
3. Mabjeesh N.J., et al. (2002) Cancer Res. 62: 2478.
4. Chavany C., et al. 1996) Amer. Society Biochem Mol Bio. 9: 4974-4977.
5. Villa R., et al. (2003) Carcinogenesis. 24(5): 851-9.
6. Yamaki H., Iguchi-Ariga S.M., and Ariga H. (1989) J Antibiot (Tokyo). 42(4): 604-10.